- Following successful medical cannabis launch in Germany, Khiron 1/14, a high CBD flower is
expected to be available in Q2/21 for UK patients
- Khiron plans to introduce additional cannabis-based medical
products with its registered strains, recently exported from
Colombia to Europe
- Supply chain improvements will increase availability of medical
cannabis for patients in the United
Kingdom
TORONTO, April 7, 2021 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, is pleased to provide an operational
update with regards to its supply of EU-GMP medical cannabis
products to the UK. To help alleviate bottlenecks and stock outs,
the Company has established an offshore inventory of dried flower,
for the express purpose of serving UK patients.
Furthermore, the Company is broadening its product portfolio by
introducing Khiron 1/14, a high-CBD flower to the UK in Q2/21. This
follows a successful launch in Germany, where it is prescribed for
indications such as anxiety, substance use disorder, and migraines.
Khiron 1/14 will complement Khiron 20/1, a high-THC flower, which
is already being prescribed to patients in the UK. Prescribing
specialists will also be able to prescribe smaller quantities of
our flower products in 5- gram jars (pictured below), thanks to
enhanced capabilities at the Company's EU-GMP certified fulfillment
partner.
Tejinder Virk, President of
Khiron Europe, commented, "The European market is growing and
Khiron is well positioned through our differentiated education
platform, mounting clinical evidence, and EU-GMP certified products
ready for prescription. Our team continues to work diligently to
increase patient access to medical cannabis products, and patients
will now benefit through greater product variety and volumes. In
the coming months, we plan to introduce additional cannabis-based
medical products from our registered Colombian strains, elevating
the level of clinical data available to medical professionals in
the UK."
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North
America. Khiron is the leading medical cannabis provider in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution and sales, and
international export of both low and high THC medical cannabis
products. The Company has filled medical cannabis prescriptions in
Colombia, Peru, Germany
and the United Kingdom, and is
positioned to commence sales in Mexico and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with KuidaTM now marketed
in multiple jurisdictions in Latin
America, the US and United
Kingdom. The Company is led by Co-founder and Chief
Executive Officer, Alvaro Torres,
together with an experienced and diverse executive team and Board
of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Investor Contact:
Paola Ricardo
E: investors@khiron.ca
T: +1 (647) 556-5750
Media Contact:
Peter
Leis
Europe Communications Manager
E: pleis.ext@khiron.ca
Khiron Europe:
Tejinder
Virk
Europe President
E: tvirk@khiron.ca
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-expands-product-offering-in-uk-and-increases-patient-access-301264063.html
SOURCE Khiron Life Sciences Corp.